secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213267
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q1 revenue falls 10% to $47.2M; net loss widens to $18.0M
------------------------------------------------------------------------

- Revenue $47.2M (-10% YoY); net loss $18.0M ($0.28 loss per share) vs $15.9M loss ($0.25) in Q1 2025.
- Adjusted EBITDA loss of $5.5M vs $(3.8)M prior year; gross margin 79.3% nearly flat.
- Cash, equivalents, and marketable securities $51.9M, up $3.5M from Dec 2025; $115M credit facility available.
- FY2026 revenue guidance reaffirmed at $202-212M (decline 5% to 0%); adjusted EBITDA loss expected $4-6M.
- CEO cites continued market share gains and case volume growth; initiated limited release of SuperBite Compression Screw System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/0001193125-26-213267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000119312526213267/tmci-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer